Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Three Amigos Stock Thread -- Ignore unavailable to you. Want to Upgrade?

To: Sergio H who wrote (21579)	10/24/2000 8:00:15 PM
From: Ken W	Read Replies (1) \| Respond to of 29382

Sergio, Hasta! Stay out of trouble. Bought some RDRT today to add to my WDC holdings..they were getting lonely. LOL RDRT reports on the 1st..may not be great but improved. The short players on the Yahoo thread are in panic mode due to the increased volume and move in price today. LOL SNAP is in the same biz as BIOI and several more...all bigger and better at what they do. Ken

To: Sergio H who wrote (21579)	10/24/2000 9:08:34 PM
From: Ken W	Respond to of 29382

Sergio, SNAP: "has enough cash to last for a while" Not for long, they say 2001..I'd say June of 01 will be the end of it or convertible debt will be the only out. The Company has incurred significant operating losses since its inception in January 1987. At December 31, 1999, the Company's accumulated deficit was $50,930,000. Losses have resulted principally from costs incurred in connection with the Company's research and development activities and from general and administrative costs associated with the Company's operations. The Company expects to continue to incur substantial operating losses at least over the next several years and expects losses to increase as research funding under its collaborative arrangements diminish. As of December 31, 1999, the only revenues generated by the Company had resulted from payments under collaborative and license agreements, and government grants under the SBIR program of the National Institutes of Health. The Company's revenues, expenses and losses may fluctuate from quarter to quarter and year to year. Research payments under the Novartis Agreements expired in 1998, research payments under the Merck Agreement expired in February 1999, and research payments under the Lilly Agreement expired in July 1999. The Company anticipates that there will 33 initially be little, if any, biological knowledge regarding many of its future gene discoveries and, as a result, it may have fewer opportunities to enter into collaborative arrangements focused on such discoveries. The Company does not expect to achieve revenues or royalties from sales of drugs for a number of years, if at all. The Company will not achieve revenues or royalties from drug sales unless it or one of its collaborative partners or other licensees successfully completes clinical trials with respect to a drug candidate, obtains regulatory approvals for that drug candidate and commercializes the resulting drug. Failure to achieve significant revenue or profitable operations could impair the Company's ability to sustain operations and there can be no assurance that the Company will ever achieve significant revenues or profitable operations. Ken